Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06963710 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
A Phase 2 study of Chronic Hepatitis B Infection, sponsored by Aligos Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06963710 is a Phase 2 study of Chronic Hepatitis B Infection that is actively recruiting participants, run by Aligos Therapeutics. The registered enrollment target is 200 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06963710, a Phase 2 study of Chronic Hepatitis B Infection, is actively recruiting participants, sponsored by Aligos Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Conditions Studied
Interventions
- DRUG ALG-000184
- DRUG TDF
Study Locations (20)
California
- Aligos Investigational Site - Coronado
- Aligos Investigational Site - Garden Grove
- Aligos Investigational Site - Los Angeles
- Aligos Investigational Site - Palo Alto
- Aligos Investigational Site - Pasadena
- Aligos Investigational Site - Rialto
- Aligos Investigational Site - San Francisco
- Aligos Investigational Site - San Jose
Florida
- Aligos Investigational Site - Miami
- Aligos Investigational Site - Miami
Maryland
- Aligos Investigational Site - Baltimore
- Aligos Investigational Site - Chevy Chase
New York
- Aligos Investigational Site - Manhasset
- Aligos Investigational Site - New York
Other
- Aligos Investigational Site - Sliven
- Aligos Investigational Sites - Sofia
Arizona
- Aligos Investigational Site - Chandler
Louisiana
- Aligos Investigational Site - Marrero
Massachusetts
- Aligos Investigational Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06963710
The ClinicalTrials.gov registry entry for NCT06963710 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepatitis B Infection appearing as the primary indexed condition, and to 2 interventions - of which ALG-000184 is the first listed.
NCT06963710 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06963710 about?
NCT06963710 is a clinical study titled "A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)". This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
What is the current status of trial NCT06963710?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-07-15. Estimated completion is 2028-08.
What conditions does trial NCT06963710 study?
This clinical trial studies the following conditions: Chronic Hepatitis B Infection.
What interventions are being tested in trial NCT06963710?
The interventions under investigation include: ALG-000184 (DRUG), TDF (DRUG).
Who is sponsoring clinical trial NCT06963710?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06963710 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.